natgillin/translations-raw huggingface dataset:
In the solvent: carmellose sodium, sodium chloride, polysorbate 20, sodium dihydrogen phosphate monohydrate, disodium phosphate heptahydrate and water for injection.
U otapalu: karmelozanatrij, natrijev klorid, polisorbat 20, natrijev dihidrogenfosfat hidrat, natrijev hidrogenfosfat heptahidrat i voda za injekcije.
In the solvent: carmellose sodium, sodium chloride, polysorbate 20, sodium dihydrogen phosphate monohydrate, disodium phosphate heptahydrate, water for injection and sodium hydroxide (for pH adjustment).
U otapalu: karmelozanatrij, natrijev klorid, polisorbat 20, natrijev dihidrogenfosfat hidrat, natrijev hidrogenfosfat heptahidrat, voda za injekcije i natrijev hidroksid (za podešavanje pH).
In the solvent: sodium chloride and water for injections
U otapalu: natrijev klorid i voda za injekcije
In the STPS, there were 84 evaluable zoster cases [8.4/1000 person-years] in the ZOSTAVAX group and 95 evaluable cases [14.0/1000 person-years] in the placebo group.
U podispitivanju STPS, moglo se procijeniti 84 slučaja herpes zostera [8,4/1000 osoba-godina] u skupini koja je primila ZOSTAVAX i 95 slučajeva [14,0/1000 osoba-godina] u skupini koja je primila placebo.
In the stratum with baseline calculated GFR above 40 mL/min, the mean and median urinary protein to creatinine ratios were significantly higher in the Rapamune conversion group as compared to those of the calcineurin inhibitors continuation group at 24 months (see section 4.4).
Nakon 24 mjeseca, u skupini s izračunatom početnom brzinom glomerularne filtracije većom od 40 ml/min, prosječne i medijan omjera proteina u urinu i kreatinina bile su značajno veće u skupini prebačenoj na Rapamune u usporedbi sa skupinom u kojoj je nastavljeno liječenje inhibitorima kalcineurina (vidjeti dio 4.4).
In the studies comparing the two strengths of insulin glargine, Toujeo 300 units/ml strength was comparable to insulin glargine (100 units/ml) at controlling sugar levels.
U ispitivanjima u kojima su uspoređene dvije jačine inzulina glargina, Toujeo jačine 300 jedinica/ml bio je usporediv s inzulinom glarginom (100 jedinica/ml) u smislu kontrole razina šećera.
In the studies in adults with schizoaffective disorder, Invega was more effective than placebo.
U ispitivanju odraslih osoba sa shizoafektivnim poremećajem, lijek Invega bio je djelotvorniji od placeba.
In the studies in newly diagnosed ovarian, fallopian tube and peritoneal cancer, average progression- free survival was 19.3 months with Avastin versus 16.9 months with carboplatin and paclitaxel alone in one study, and 14.7 months versus 10.6 months in the second study.
U ispitivanjima provedenima na novodijagnosticiranim rakovima jajnika, jajovoda i peritoneuma, prosječno razdoblje preživljenja bez progresije iznosilo je 19,3 mjeseci s lijekom Avastin u odnosu na 16,9 mjeseci samo s lijekovima karboplatin i paklitaksel u jednom ispitivanju, i 14,7 mjeseci u odnosu na 10,6 mjeseci u drugom ispitivanju.
In the studies in patients with earlier stages of breast cancer who were to undergo surgery, Perjeta was shown to improve response to treatment.
U ispitivanjima provedenima u bolesnika s ranijim stadijima raka dojke koji su trebali biti podvrgnuti kirurškom zahvatu, dokazano je da je Perjeta poboljšao odgovor na terapiju.
In the studies in the treatment and prevention of swine dysentery, Econor in feed at a dose of 3-4 mg valnemulin/kg bodyweight/day (i.e.
U studijama liječenja i prevencije svinjske dizenterije, Econor u hrani pri dozi od 3-4 mg valnemulina/kg tjelesne težine/dan (tj.
In the studies in the treatment and prevention of swine enzootic pneumonia, Econor in feed at a dose of 10-12 mg valnemulin/kg bodyweight (i.e.
U ispitivanjima liječenja i prevencije svinjske enzootske pneumonije Econor u hrani pri dozi od 10- 12 mg valnemulina/kg tjelesne težine (tj.
In the studies looking at the dispersible tablets, the levels of bosentan were lower than expected from the results of other studies, and could not be increased by using a higher dosing of Tracleer.
U ispitivanjima koja su istražila disperzibilne tablete, razine bosentana bile su niže od očekivanih na temelju rezultata drugih ispitivanja, i nisu se mogla povećati primjenom veće doze lijeka Tracleer.
In the studies looking at treatment of VTE and PE, blood clots or blood-clot related death occurred in 2.7% (68 out of 2553) of patients treated with Pradaxa, compared with 2.4% (62 out of 2554) of patients treated with warfarin.
U ispitivanjima koja su istražila liječenje VTE-a i PE-a, krvni ugrušci ili smrtni slučajevi povezani s krvnim ugrušcima zabilježeni su u 2,7 % (68 od 2 553) bolesnika koji su liječeni lijekom Pradaxa, u usporedbi s 2,4 % (62 od 2 554) bolesnika koji su liječeni varfarinom.
In the studies of cancer of the colon or rectum, Erbitux was shown overall to increase the time patients lived without their cancer getting worse or how long they survived: in patients who had not received chemotherapy before, patients who had wild-type KRAS in their tumours lived for longer without their disease getting worse when they received Erbitux in addition to chemotherapy including irinotecan (9.9 months compared with 8.4 months, on average).
U ispitivanjima karcinoma kolona ili rektuma, načelno je dokazano da lijek Erbitux produžava vrijeme tijekom kojeg su bolesnici živjeli bez pogoršanja raka ili vrijeme preživljenja: u bolesnika koji nisu prethodno primili kemoterapiju, bolesnici koji su imali KRAS divljeg tipa u svojim tumorima živjeli su dulje, a da se njihova bolest nije pogoršala, nakon što su primili lijek Erbitux uz kemoterapiju koja je uključivala irinotekan (prosječno 9,9 mjeseci u usporedbi s 8,4 mjeseci).
In the studies of Invirase in combination with ritonavir, Invirase was as effective as indinavir, but more effective than lopinavir in reducing the viral load to less than 50 copies/ml.
U ispitivanjima lijeka Invirase u kombinaciji s ritonavirom Invirase se pokazao jednako djelotvornim kao indinavir, ali djelotvornijim od lopinavira u smanjenju virusnog opterećenja na manje od 50 kopija/ml.
In the studies of patients with BH4 deficiency, patients showed an improvement in blood phenylalanine levels and other markers of the disease when they were taking sapropterin dihydrochloride.
U ispitivanjima bolesnika s nedostatkom BH4, bolesnici koji su uzimali sapropterin dihidroklorid demonstrirali su poboljšanje u koncentraciji fenilalanina u krvi i drugim markerima ove bolesti.
In the studies of PI-experienced adult patients, APV30003 and its extension, APV30005 (fosamprenavir 700 mg / ritonavir 100 mg twice daily: n=107), the following mutations emerged in patients experiencing virological failure through 96 weeks: L10F/I, L24I, V32I, L33F, M36I, M46I/L, I47V, I50V, I54L/M/S, A71I/T/V, G73S, V82A, I84V, and L90M.
U ispitivanjima na odraslim bolesnicima koji su ranije primali terapiju s IP, ispitivanju APV30003 i njegovoj ekstenziji, APV30005 (fosamprenavir 700 mg/ritonavir 100 mg 2 puta dnevno: n=107), kod bolesnika s virološkim neuspjehom kroz 96. tjedana pojavile su se sljedeće mutacije: L10F/I, L24I, V32I, L33F, M36I, M46I/L, I47V, I50V, I54L/M/S, A71I/T/V, G73S, V82A, I84V i L90M.
In the studies of PI-experienced adult patients, PRO30017 (amprenavir 600 mg / ritonavir 100 mg twice daily in sub-study A and B with 80 and 37 patients respectively), the following mutations emerged in patients with virological failure: L10F/I/V, V11I, I13V, K20R, V32I, L33F, E34Q, M36I, M46I/L, I47V, G48V, I50V, I54L/M/T/V, Q58E, D60E, I62V, A71V, V77I, V82A/I, I84V, I85V, L90M and I93L/M.
U ispitivanjima na odraslim bolesnicima koji su ranije primali terapiju s IP, ispitivanju PRO30017 (amprenavir 600 mg/ritonavir 100 mg dva puta dnevno u podispitivanjima A i B u koje je bilo uključeno 80 odnosno 37 bolesnika), kod bolesnika s virološkim neuspjehom pojavile su se sljedeće mutacije: L10F/I/V, V11I, I13V, K20R, V32I, L33F, E34Q, M36I, M46I/L, I47V, G48V, I50V, I54L/M/T/V, Q58E, D60E, I62V, A71V, V77I, V82A/I, I84V, I85V, L90M i I93L/M.
In the studies of skin and soft tissue infections in adults, the success rates at seven to 12 days after the last injection of Cubicin were 67% in one study and 85% in the other.
U ispitivanjima infekcija kože i mekog tkiva u odraslih stope uspješnosti sedam do 12 dana nakon posljednje injekcije Cubicina iznosile su 67 % u jednom ispitivanju te 85 % u drugom.
In the studies, Orkambi was compared with placebo (a dummy treatment), both added to patients’ usual therapy.
U ispitivanjima je Orkambi uspoređen s placebom (prividno liječenje) te su oba dodana uobičajenoj terapiji bolesnika.
In the studies, SevoFlo was equally effective when compared to other anaesthetic agents.
U navedenim ispitivanjima SevoFlo se pokazao jednako učinkovitim u usporedbi s ostalim anesteticima.
In the study carried out during an epidemic, 1% of the people taking Tamiflu developed flu after contact, compared with 5% of those taking placebo.
U ispitivanju provedenom tijekom epidemije, 1% osoba koje su uzimale lijek Tamiflu razvilo je grupu nakon kontakta, u usporedbi s 5% onih koji su uzimali placebo.
In the study comparing Eliquis with warfarin, 1.3 % of the patients taking Eliquis had a stroke or clotting event every year compared with 1.6% of the patients taking warfarin.
U ispitivanju koje je usporedilo Eliquis s warfarinom, 1,3 % bolesnika koji su uzimali Eliquis imalo je moždani udar ili ugrušak svake godine u usporedbi s 1,6% bolesnika koji su uzimali warfarin.
In the study comparing Incruse with tiotropium, FEV1 improvements over 24 weeks were similar for both medicines.
U ispitivanju koje je usporedilo lijek Incruse s tiotropijem, poboljšanja FEV1 tijekom 24 tjedna bila su slična za oba lijeka.
In the study in adults, 62.8% (27 out of 43) of patients who received Revestive responded to treatment, compared with 30.2% (13 out of 43) who received placebo.
Tijekom ispitivanja provedenog na odraslima, 62,8% bolesnika (njih 27 od 43) ostvarilo je pozitivan rezultat liječenja, u usporedbi s 30,2% bolesnika (njih 13 od 43) koji su primali placebo.
In the study in children aged 2 to 5 years, Kalydeco granules had a positive effect on bodyweight and the amount of chloride contained in sweat.
U ispitivanju kod djece u dobi od 2 do 5 godina, Kalydeco granule imale su pozitivan učinak na tjelesnu težinu i količinu klorida u znoju.
In the study in children aged 4 weeks to 2 years Isentress treatment led to a reduction in viral load and after 48 weeks 53% of the children had viral loads below 50 copies/ml.
U ispitivanju djece u dobi od 4 tjedna do 2 godine, liječenje lijekom Isentress rezultiralo je smanjenjem virusnog opterećenja, a nakon 48 tjedana 53% djece imalo je virusno opterećenje manje od 50 kopija/ml.
In the study in children and adolescents, Abilify was also more effective than placebo at reducing the manic symptoms of bipolar disorder.
U ispitivanju na djeci i adolescentima Abilify se također pokazao djelotvornijim od placeba u redukciji maničnih simptoma bipolarnog poremećaja.
In the study in children, six out of seven patients did not need any transfusion of red blood cell and haemoglobin levels improved during treatment with Soliris.
U ispitivanju provedenom u djece, šest od sedam bolesnika nije trebalo nikakvu transfuziju crvenih krvnih stanica, a razine hemoglobina su se povećale tijekom liječenja lijekom Soliris.
In the study in children/adolescents aged 1 – 18 years with de novo ALL (study MC-ASP.5/ALL), by day 33 of induction treatment 10 patients in the Spectrila group (10.3 %) and 9 in the reference group (8.9 %) were measured positive for anti-asparaginase antibodies at least at one time point.
U ispitivanju provedenom na djeci/adolescentima u dobi od 1 do 18 godina s de novo ALL (ispitivanje MC-ASP.5/ALL), do 33. dana indukcijskog liječenja ustanovljeno je da je 10 bolesnika u skupini koja je primala Spectrilu (10,3%), a 9 u referentnoj skupini (8,9%) bilo pozitivno na protutijela protiv asparaginaze u najmanje jednoj vremenskoj točki.
In the study in metastatic disease, patients treated with Perjeta lived for longer without their disease getting worse than patients given placebo.
U ispitivanju metastatske bolesti, bolesnici liječeni lijekom Perjeta živjeli su dulje bez pogoršanja bolesti u odnosu na bolesnike koji su primali placebo.
In the study in metastatic pancreatic cancer, patients taking Tarceva as initial therapy survived without their disease getting worse for an average of 5.9 months, compared with 5.1 months in those taking placebo.
U ispitivanju na bolesnicima s metastatskim rakom gušterače, bolesnici koji su uzimali lijek Tarceva kao početnu terapiju živjeli su u prosjeku 5,9 mjeseci bez pogoršanja bolesti u usporedbi s bolesnicima koji su uzimali placebo koji su živjeli u prosjeku 5,1 mjeseci bez pogoršanja bolesti.
In the study in neurological surgery, TachoSil was comparable to current techniques: around 7% (25 out of 361) of patients treated with TachoSil had a leak of CSF, compared with around 8% (30 out of
U ispitivanju kod neuroloških operacija TachoSil je bio usporediv s postojećim tehnikama: kod oko 7% (25 od 361) bolesnika liječenih TachoSilom došlo je do istjecanja CSF-a u usporedbi s oko 8% (30 od
In the study in patients whose disease had not responded to previous treatment, 49% of the patients whose previous treatment with both fludarabine and alemtuzumab had failed (47 out of 95) responded to treatment with Arzerra.
U ispitivanju provedenom među bolesnicima koji nisu odgovorili na prethodnu terapiju, 49 % bolesnika kod kojih prethodno nije uspjela niti terapija fludarabinom niti terapija alemtuzumabom (47 od 95 bolesnika) odgovorilo je na terapiju lijekom Arzerra.
In the study in patients with more aggressive cancer, progression-free survival was 6.7 months when Avastin was added to paclitaxel, topotecan, or pegylated liposomal doxorubicin, compared with 3.4 months when these chemotherapies were used on their own.
U ispitivanju u bolesnika s agresivnijim rakom, preživljenje bez progresije iznosilo je 6,7 mjeseci u slučaju kada je Avastin dodan paklitakselu, topotekanu ili pegiliranom liposomalnom doksorubicinu, u usporedbi s 3,4 mjeseca u slučaju kada su te kemoterapije korištene samostalno.
In the study in patients with unresectable and/or metastatic GIST, 7 (5%) patients experienced CTC grade 3/4 GI bleeds (3 patients), intra-tumoural bleeds (3 patients) or both (1 patient).
U ispitivanju kod bolesnika s inoperabilnim i/ili metastazirajućim GIST-om, u 7 (5%) bolesnika nastupilo je GI krvarenje CTC stupnja 3/4 (3 bolesnika), intratumorsko krvarenje (3 bolesnika) ili oboje (1 bolesnik).
In the study in patients with unresectable and/or metastatic GIST, 7 (5%) patients experienced CTC grade 3/4 GI bleeds (3patients), intra-tumoural bleeds (3patients) or both (1patient).
U ispitivanju s bolesnicima s inoperabilnim i/ili metastazirajućim GIST-om, u 7 (5%) bolesnika nastupilo je GI krvarenje CTC stupnja 3/4 (3 bolesnika), intratumorsko krvarenje (3 bolesnika) ili oboje (1 bolesnik).
In the study in patients with unresectable and/or metastatic GIST, both gastrointestinal and intra- tumoural haemorrhages were reported (see section 4.8).
U ispitivanju s bolesnicima s inoperabilnim i/ili metastazirajućim GIST-om zabilježena su i gastrointestinalna i intratumorska krvarenja (vidjeti dio 4.8).
In the study in patients with unresectable and/or metastatic GIST, grade 3 and 4 anaemia was reported in 5.4% and 0.7% of patients, respectively, and may have been related to gastrointestinal or intra- tumoural bleeding in at least some of these patients.
U ispitivanju s bolesnicima s inoperabilnim i/ili metastazirajućim GIST-om, anemija 3. i 4. stupnja zabilježena je u 5,4% odnosno 0,7% bolesnika i mogla je biti povezana s gastrointestinalnim ili intratumorskim krvarenjem barem u nekih od tih bolesnika.
In the study in patients with unresectable and/or metastatic GIST, grade 3 and 4 anaemia was reported in 5.4% and 0.7% of patients, respectively, and may have been related to gastrointestinal or intra- tumoural bleeding in at least some of these patients.
U ispitivanju s bolesnicima s inoperabilnim i/ili metastazirajućim GIST-om, anemije 3. i 4. stupnja zabilježene su u 5,4% odnosno 0,7% bolesnika i mogle su biti povezane s gastrointestinalnim ili intratumorskim krvarenjem barem u nekih od tih bolesnika.
In the study in patients with unresectable and/or metastatic GIST, grade3 and 4 anaemia was reported in 5.4% and 0.7% of patients, respectively, and may have been related to gastrointestinal or intra- tumoural bleeding in at least some of these patients.
U ispitivanju s bolesnicima s inoperabilnim i/ili metastazirajućim GIST-om, anemije 3. i 4. stupnja zabilježene su u 5,4% odnosno 0,7% bolesnika i mogle su biti povezane s gastrointestinalnim ili intratumorskim krvarenjem barem u nekih od tih bolesnika.
In the study in previously treated patients, those treated with Xalkori lived on average for nearly 8 months without their disease getting worse compared with 3 months in patients who were treated with either pemetrexed or docetaxel.
Tijekom ispitivanja među bolesnicima koji su prethodno liječeni, oni koji su primili Xalkori živjeli su u prosjeku gotovo osam mjeseci bez pogoršanja bolesti u usporedbi s tri mjeseca u bolesnika koji su liječeni pemetreksedom ili docetakselom.
In the study in previously untreated patients, those treated with Xalkori lived on average for nearly 11 months without their disease getting worse compared with 7 months in patients who were treated with pemetrexed-containing therapy.
Tijekom ispitivanja među bolesnicima koji nisu prethodno liječeni, oni koji su primili Xalkori živjeli su u prosjeku gotovo 11 mjeseci bez pogoršanja bolesti, a bolesnici koji su primili terapiju koja je sadržavala pemetreksed sedam mjeseci.
In the study in rabbits mortality was reduced from 23% in untreated rabbits to 11% in those given 20 mg valnemulin per kg of feed, and about 8% in those given 35 mg valnemulin per kg feed.
U studiji na zečevima smrtnost je smanjena s 23% u neliječenih životinja na 11% u onih koji su primali 20 mg valnemulina po kg hrane te za otprilike 8% u onih koji su primali 35 mg valnemulina po kg hrane.
In the study in which NovoSeven was given in the home setting, 90% of the bleeding episodes were controlled effectively.
U ispitivanju u kojemu je lijek NovoSeven primijenjen u kućnom liječenju, 90 % epizoda krvarenja učinkovito je kontrolirano.
In the study looking at otitis media, the investigational vaccine containing the same polysaccharides as Synflorix was more effective than the comparator in preventing otitis media.
U ispitivanju koje je istražilo otitis media, ispitivano cjepivo koje je sadržavalo iste polisaharide kao Synflorix bilo je učinkovitije od komparatora u sprječavanju otitis media.
In the study of Glanzmann’s thrombasthenia, treatment with NovoSeven was successful in 74% of the bleeds (42 out of 57).
U ispitivanju koje je uključivalo bolesnike s Glanzmannovom trombastenijom liječenje lijekom NovoSeven bilo je uspješno u 74 % krvarenja (42 od 57).
In the study of ovarian, fallopian tube and peritoneal cancer that came back 6 month or more after previous chemotherapy, average progression-free survival was 12.4 months when Avastin was added to carboplatin and gemcitabine, compared with 8.4 months when placebo was added.
U ispitivanju raka jajnika, jajovoda i peritoneuma koji se vratio nakon 6 mjeseci ili više od prethodne kemoterapije, prosječno razdoblje preživljenja bez progresije iznosilo je 12,4 mjeseca u slučaju kada je Avastin dodan u karboplatin i gemcitabin, u odnosu na 8,4 mjeseci u slučaju kada je dodan placebo.
In the study of patients undergoing hip replacement, blood clots were detected in 6% of the patients taking 220 mg Pradaxa (50 out of 880), compared with 7% of the patients receiving enoxaparin (60 out of 897).
U ispitivanju kod bolesnika koji su podvrgnuti operaciji zamjene kuka, krvni su ugrušci otkriveni u 6 % bolesnika koji su uzimali lijek Pradaxa od 220 mg (50 od 880), u usporedbi sa 7 % bolesnika koji su primali enoksaparin (60 od 897).
In the study of patients undergoing knee replacement, blood clots were detected in 36% of the patients taking the 220 mg dose of Pradaxa (182 out of 503), compared with 38% of the patients receiving enoxaparin (192 out of 512).
U ispitivanju kod bolesnika koji su podvrgnuti operaciji zamjene koljena, krvni su ugrušci otkriveni u 36 % bolesnika koji su uzimali dozu od 220 mg lijeka Pradaxa (182 od 503), u donosu na 38 % bolesnika koji su uzimali enoksaparin (192 od 512).
In the study of patients who had not previously received methotrexate, adding Orencia and methotrexate to existing treatment for 12 months led to a reduction in symptoms in 61% of the patients (70 out of 115), compared with 42% of the patients on Orencia alone (48 out of 113) and 45% of the patients on methotrexate alone (52 out of 115).
U ispitivanju na bolesnicima koji u prošlosti nisu uzimali metotreksat, dodavanjem lijeka Orencia i metotreksata postojećoj terapiji tijekom 12 mjeseci došlo je do ublažavanja simptoma kod 61 % bolesnika (70 od 115), u usporedbi s 42 % bolesnika koji su uzimali samo lijek Orencia (48 od 113) i 45 % bolesnika koji su uzimali samo metotreksat (52 od 115).
In the study of patients whose spleen had been removed, 38% of the patients had a lasting response to treatment with Nplate (16 out of 42), compared with none of the 21 patients receiving placebo.
U ispitivanju bolesnika kojima je odstranjena slezena njih 38 % imalo je dugotrajan pozitivan odgovor na terapiju lijekom Nplate (16 od 42), u usporedbi s nijednim od 21 bolesnika koji je primao placebo.
In the study of patients with a single clinical event suggestive of multiple sclerosis, neutralising activity measured every 6 months was observed at least once in 32% (89) of the patients treated immediately with Betaferon; of these, 60% (53) returned to negative status based on the last available assessment within the 5 year period.
U ispitivanju bolesnika s pojedinačnim kliničkim događajem koji ukazuje na multiplu sklerozu, neutralizirajuća aktivnost mjerena svakih 6 mjeseci zabilježena je barem jedanput u 32 % (89) bolesnika koji su odmah bili liječeni lijekom Betaferon; od toga, njih 60 % (53) vratilo je negativan status na temelju posljednje dostupne procjene unutar petogodišnjeg razdoblja.
In the study of patients with a spleen, 61% of the patients had a lasting response to treatment with Nplate (25 out of 41), compared with 5% of the patients receiving placebo (1 out of 21).
U ispitivanju bolesnika kojima slezena nije odstranjena 61 % bolesnika imao je dugotrajan pozitivan odgovor na terapiju lijekom Nplate (25 od 41), u usporedbi s 5 % bolesnika koji su primali placebo (1 od 21).
In the study of patients with anaemia caused by kidney problems, patients switching to Abseamed maintained haemoglobin levels to the same extent as those continuing to take Eprex/Erypo.
U ispitivanju bolesnika s anemijom uzrokovanom problemima s bubrezima, bolesnici koji su prešli na Abseamed zadržali su koncentracije hemoglobina na istoj razini kao oni koji su nastavili uzimati Eprex/Erypo.
In the study of patients with anaemia caused by kidney problems, patients switching to Binocrit maintained haemoglobin levels to the same extent as those continuing to take Eprex/Erypo.
U ispitivanju bolesnika s anemijom uzrokovanom problemima s bubrezima, bolesnici koji su prešli na Binocrit zadržali su koncentracije hemoglobina na istoj razini kao oni koji su nastavili uzimati Eprex/Erypo.
In the study of patients with anaemia caused by kidney problems, patients switching to Epoetin Alfa Hexal maintained haemoglobin levels to the same extent as those continuing to take Eprex/Erypo.
U ispitivanju bolesnika s anemijom uzrokovanom problemima s bubrezima, bolesnici koji su prešli na Epoetin Alfa Hexal zadržali su koncentracije hemoglobina na istoj razini kao oni koji su nastavili uzimati Eprex/Erypo.